Completion of Patient Visits in Nispomeben Trial
Novaremed AG is excited to announce a significant milestone: the completion of the last patient visit in its Phase 2b trial evaluating nispomeben (NRD.E1) for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). This clinical study, organized with support from the National Institutes of Health, marks an important step forward for non-opioid pain management solutions.
Overview of the Phase 2b Trial
The recently concluded trial involved 127 adult and elderly patients who participated in a 12-week placebo-controlled study designed to assess the efficacy of nispomeben. As per clinical protocol, the study facilitates precise analysis of the drug's performance compared to placebo.
Trial Protocol and Objectives
This Phase 2b trial aimed to investigate whether a once-daily oral dose of nispomeben (80 mg) could outshine its placebo counterpart in alleviating chronic pain in DPN patients. The trial also explored safety, tolerability, pharmacokinetics, and its effect on sleep quality and overall life quality among participants. With the last patient visit now achieved, the focus shifts to data analysis and statistical evaluation, with topline results anticipated in November 2025.
Insights from Medical Experts
Dr. Jessica Robinson-Papp, the Lead Investigator and an esteemed professor at the Icahn School of Medicine, expressed her enthusiasm about reaching this milestone. Over 20% of diabetes patients suffer from painful DPN, which significantly impacts their quality of life. Dr. Robinson-Papp noted, "I'm thankful to all the participants and collaborating sites for their dedication to this rigorous study—their contribution is invaluable to advancing this program. We are eager to analyze the results and share them with the community."
Significance of Nispomeben
Nispomeben is pioneering a new wave of pain management treatments with a unique mechanism of action that sets it apart from traditional pain therapies, particularly opioids. This investigational medication does not engage with opioid receptors or other pathways associated with opioid function, thus presenting an attractive option for patients seeking relief without the associated risks of addiction. The FDA has granted Fast Track designation to nispomeben, acknowledging its potential to address an urgent medical need.
Background on Painful DPN
Painful diabetic peripheral neuropathy is a common complication faced by diabetes patients. The condition leads to debilitating chronic pain, with an alarming two-thirds of patients unable to achieve sufficient relief through current treatments. This knowledge drives Novaremed's commitment to develop innovative, non-addictive therapeutic alternatives that address these pressing needs. The growing prevalence of diabetes underscores the importance of effectively managing painful DPN.
Future Directions
Camilla Mittelholzer, PhD and Chief Scientific Officer at Novaremed, added, "Completing all patient visits is a monumental achievement in our fight against painful DPN. We are enthusiastic about the continued investigation of nispomeben, a critical player in our effort to provide new and effective pain management therapies. Our team is dedicated to transforming the landscape of pain management with safer and more effective options for patients. We appreciate the NIH's support in selecting nispomeben as a leading candidate in this space."
Frequently Asked Questions
What is nispomeben?
Nispomeben is an investigational non-opioid therapy under development to treat chronic pain associated with diabetic peripheral neuropathy.
When will the results of the Phase 2b trial be available?
The topline results are expected to be released in November 2025 after thorough analysis of the data is complete.
Why is nispomeben significant?
Nispomeben offers a novel mechanism of action for pain relief without engaging opioid receptors, aiming to provide safe alternatives for patients struggling with pain.
How does painful DPN affect patients?
Painful diabetic peripheral neuropathy can lead to severe chronic pain, significantly affecting the quality of life for approximately 20% of diabetes patients.
What are the next steps in the development of nispomeben?
Following the completion of patient visits, the focus will shift to database lock and detailed statistical analyses before the upcoming release of study findings.
